BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 16550002)

  • 1. In-vitro differential metabolism and activity of 5-fluorouracil between short-term, high-dose and long-term, low-dose treatments in human squamous carcinoma cells.
    Qin B; Tanaka R; Ariyama H; Shibata Y; Arita S; Kusaba H; Baba E; Harada M; Nakano S
    Anticancer Drugs; 2006 Apr; 17(4):439-43. PubMed ID: 16550002
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged and enhanced suppression of thymidylate synthase by weekly 24-h infusion of high-dose 5-fluorouracil.
    Yeh KH; Yeh SH; Hsu CH; Wang TM; Ma IF; Cheng AL
    Br J Cancer; 2000 Dec; 83(11):1510-5. PubMed ID: 11076661
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytotoxic effects and mechanisms of an alteration in the dose and duration of 5-fluorouracil.
    Patel M; Ardalan K; Hochman I; Tian EM; Ardalan B
    Anticancer Res; 2003; 23(1A):447-52. PubMed ID: 12680247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlations between thymidylate synthase expression and chemosensitivity to 5-fluorouracil, cell proliferation and clinical outcome in head and neck squamous cell carcinoma.
    Yasumatsu R; Nakashima T; Uryu H; Ayada T; Wakasaki T; Kogo R; Masuda M; Fukushima M; Komune S
    Chemotherapy; 2009; 55(1):36-41. PubMed ID: 19023200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
    Ford HE; Mitchell F; Cunningham D; Farrugia DC; Hill ME; Rees C; Calvert AH; Judson IR; Jackman AL
    Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation between clinicopathologic factors and kinetics of metabolic enzymes for 5-fluorouracil given to patients with colon carcinoma by two different dosage regimens.
    Katsumata K; Tomioka H; Sumi T; Yamashita S; Takagi M; Kato F; Nakamura R; Koyanagi Y; Aoki T; Kato K
    Cancer Chemother Pharmacol; 2003 Feb; 51(2):155-60. PubMed ID: 12647017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects on DNA and RNA after the administration of two different schedules of 5-fluorouracil in colorectal cancer patients.
    Hoshino S; Yamashita Y; Maekawa T; Shirakusa T
    Cancer Chemother Pharmacol; 2005 Dec; 56(6):648-52. PubMed ID: 15959779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fluoropyrimidine chemotherapy in a rat model: comparison of fluorouracil metabolite profiles determined by high-field 19F-NMR spectroscopy of tissues ex vivo with therapy response and toxicity for locoregional vs systemic infusion protocols.
    Lutz NW; Naser-Hijazi B; Koroma S; Berger MR; Hull WE
    NMR Biomed; 2004 May; 17(3):101-31. PubMed ID: 15137037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro synergism between 5-fluorouracil and natural beta interferon in human colon carcinoma cells.
    Guglielmi A; Aschele C; Mori A; Baldo C; Russo P; Debernardis D; Valenti M; Bruno S; Taverna M; Rosso R
    Clin Cancer Res; 1995 Nov; 1(11):1337-44. PubMed ID: 9815929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between p53 status and 5-fluorouracil sensitivity in 3 cell lines.
    Oka H; Ikeda K; Yoshimura H; Ohuchida A; Honma M
    Mutat Res; 2006 Jul; 606(1-2):52-60. PubMed ID: 16584912
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression level of thymidylate synthase mRNA reflects 5-fluorouracil sensitivity with low dose and long duration in primary colorectal cancer.
    Okumura K; Mekata E; Shiomi H; Naitoh H; Abe H; Endo Y; Kurumi Y; Tani T
    Cancer Chemother Pharmacol; 2008 Apr; 61(4):587-94. PubMed ID: 17520254
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pretreatment with 5-FU enhances cisplatin cytotoxicity in head and neck squamous cell carcinoma cells.
    Ijichi K; Adachi M; Hasegawa Y; Ogawa T; Nakamura H; Kudoh A; Yasui Y; Murakami S; Ishizaki K
    Cancer Chemother Pharmacol; 2008 Oct; 62(5):745-52. PubMed ID: 18075740
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic and biochemical modulation of 5-fluorouracil through the overexpression of thymidine kinase: an in-vitro study.
    Fanciullino R; Evrard A; Cuq P; Giacometti S; Peillard L; Mercier C; Aubert C; Milano G; Ciccolini J
    Anticancer Drugs; 2006 Apr; 17(4):463-70. PubMed ID: 16550005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [In vitro studies of 5-FU sensitivity on uterine cervical cancer cell lines--comparison between squamous cell carcinoma and adenocarcinoma].
    Ueda M; Misaki O; Yamada T; Okamoto Y; Goto M; Maeda T; Okamura S; Ueki M; Sugimoto O
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Sep; 41(9):1423-30. PubMed ID: 2531191
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sequential methotrexate and 5-fluorouracil: mechanisms of synergy.
    Bertino JR; Mini E; Fernandes DJ
    Semin Oncol; 1983 Jun; 10(2 Suppl 2):2-5. PubMed ID: 6867754
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical determinants of 5-fluorouracil response in vivo. The role of deoxyuridylate pool expansion.
    Myers CE; Young RC; Chabner BA
    J Clin Invest; 1975 Nov; 56(5):1231-8. PubMed ID: 1184747
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Establishment of a multidrug-resistant cell line BEL-7402/5-FU of human hepatocellular carcinoma and its biological characteristics].
    Gu W; Zhang YN; Li B; Han J; Cheng BB; Ling CQ
    Zhong Xi Yi Jie He Xue Bao; 2006 May; 4(3):265-70. PubMed ID: 16696913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mechanisms of acquired chemoresistance to 5-fluorouracil and tomudex: thymidylate synthase dependent and independent networks.
    Wang W; McLeod HL; Cassidy J; Collie-Duguid ES
    Cancer Chemother Pharmacol; 2007 May; 59(6):839-45. PubMed ID: 17119966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Theoretical construction of chemotherapeutic tactics for advanced or recurrent gastrointestinal carcinoma].
    Omura K; Kawakami K; Kanehira E
    Gan To Kagaku Ryoho; 2001 Jan; 28(1):63-8. PubMed ID: 11201382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apoptosis, cell cycle progression and gene expression in TP53-depleted HCT116 colon cancer cells in response to short-term 5-fluorouracil treatment.
    Adamsen BL; Kravik KL; Clausen OP; De Angelis PM
    Int J Oncol; 2007 Dec; 31(6):1491-500. PubMed ID: 17982676
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.